Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G‑CSF therapies
Structure, Thermodynamics, and Kinetics of Plinabulin Binding to Two Tubulin Isotypes
GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-Tumor Responses
Phase 1 Study of the Novel Vascular Disrupting Agent Plinabulin (NPI-2358) and Docetaxel
Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas
© 2020 BeyondSpring Inc. All rights reserved.